{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T04:16:26Z","timestamp":1792988186928,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s00277-024-05857-y","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T01:01:31Z","timestamp":1719277291000},"page":"2721-2727","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The long-term efficacy of eltrombopag in children with immune thrombocytopenia"],"prefix":"10.1007","volume":"103","author":[{"given":"Li-","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao-Hua","family":"Sang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Hui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zu-Gang","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Lian","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Min","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-Wen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ti-Long","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,25]]},"reference":[{"issue":"1","key":"5857_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/bjh.19075","volume":"203","author":"DM Arnold","year":"2023","unstructured":"Arnold DM et al (2023) Refractory immune thrombocytopenia in adults: towards a new definition. Br J Haematol 203(1):23\u201327","journal-title":"Br J Haematol"},{"key":"5857_CR2","doi-asserted-by":"publisher","first-page":"100822","DOI":"10.1016\/j.blre.2021.100822","volume":"49","author":"M Kochhar","year":"2021","unstructured":"Kochhar M, Neunert C (2021) Immune Thrombocytopenia: a review of upfront treatment strategies. Blood Rev 49:100822","journal-title":"Blood Rev"},{"key":"5857_CR3","doi-asserted-by":"publisher","first-page":"1215216","DOI":"10.3389\/fimmu.2023.1215216","volume":"14","author":"Z Xiao","year":"2023","unstructured":"Xiao Z, Murakhovskaya I (2023) Rituximab resistance in ITP and beyond. Front Immunol 14:1215216","journal-title":"Front Immunol"},{"key":"5857_CR4","doi-asserted-by":"publisher","first-page":"101112","DOI":"10.1016\/j.blre.2023.101112","volume":"61","author":"TJ Gonz\u00e1lez-L\u00f3pez","year":"2023","unstructured":"Gonz\u00e1lez-L\u00f3pez TJ et al (2023) Primary and secondary immune thrombocytopenia (ITP): time for a rethink. Blood Rev 61:101112","journal-title":"Blood Rev"},{"key":"5857_CR5","doi-asserted-by":"publisher","first-page":"103820","DOI":"10.1016\/j.ebiom.2022.103820","volume":"76","author":"D Provan","year":"2022","unstructured":"Provan D, Semple JW (2022) Recent advances in the mechanisms and treatment of immune thrombocytopenia. EBioMedicine 76:103820","journal-title":"EBioMedicine"},{"issue":"22","key":"5857_CR6","doi-asserted-by":"publisher","first-page":"4457","DOI":"10.1182\/blood-2012-12-466375","volume":"121","author":"CE Neunert","year":"2013","unstructured":"Neunert CE et al (2013) Bleeding manifestations and management of children with persistent and chronic immune thrombocytopenia: data from the Intercontinental Cooperative ITP Study Group (ICIS). Blood 121(22):4457\u20134462","journal-title":"Blood"},{"key":"5857_CR7","doi-asserted-by":"crossref","unstructured":"Bennett CM et al (2018) Predictors of remission in children with newly diagnosed immune thrombocytopenia: data from the Intercontinental Cooperative ITP Study Group Registry II participants. Pediatr Blood Cancer, 65(1)","DOI":"10.1002\/pbc.26736"},{"key":"5857_CR8","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ejim.2022.11.022","volume":"108","author":"A Gafter-Gvili","year":"2023","unstructured":"Gafter-Gvili A (2023) Current approaches for the diagnosis and management of immune thrombocytopenia. Eur J Intern Med 108:18\u201324","journal-title":"Eur J Intern Med"},{"issue":"3","key":"5857_CR9","first-page":"196","volume":"158","author":"D Blickstein","year":"2019","unstructured":"Blickstein D (2019) [Treatment of immune thrombocytopenic purpura in adults: update]. Harefuah 158(3):196\u2013199","journal-title":"Harefuah"},{"issue":"4 Suppl 5","key":"5857_CR10","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1053\/j.seminhematol.2007.11.003","volume":"44","author":"DM Arnold","year":"2007","unstructured":"Arnold DM, Kelton JG (2007) Current options for the treatment of idiopathic thrombocytopenic purpura. Semin Hematol 44(4 Suppl 5):S12\u201323","journal-title":"Semin Hematol"},{"issue":"23","key":"5857_CR11","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","volume":"3","author":"C Neunert","year":"2019","unstructured":"Neunert C et al (2019) American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 3(23):3829\u20133866","journal-title":"Blood Adv"},{"key":"5857_CR12","doi-asserted-by":"crossref","unstructured":"de Torelli B (2023) D.F.H., Eltrombopag for adults and children with Immune-Refractory Thrombocytopenic Purpura: a systematic review. J Clin Med, 12(12)","DOI":"10.3390\/jcm12123872"},{"issue":"1","key":"5857_CR13","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1158\/1078-0432.CCR-22-1457","volume":"29","author":"JD Gonzalez-Lugo","year":"2023","unstructured":"Gonzalez-Lugo JD et al (2023) Lenalidomide and Eltrombopag for treatment of low- or intermediate-risk myelodysplastic syndrome: result of a phase II clinical trial. Clin Cancer Res 29(1):60\u201366","journal-title":"Clin Cancer Res"},{"issue":"4","key":"5857_CR14","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1182\/bloodadvances.2017010660","volume":"2","author":"TO Kim","year":"2018","unstructured":"Kim TO, Despotovic J, Lambert MP (2018) Eltrombopag for use in children with immune thrombocytopenia. Blood Adv 2(4):454\u2013461","journal-title":"Blood Adv"},{"issue":"2","key":"5857_CR15","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/bjh.17334","volume":"193","author":"E Lucchini","year":"2021","unstructured":"Lucchini E et al (2021) Eltrombopag second-line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off-treatment: results of a phase II, multicentre, prospective study. Br J Haematol 193(2):386\u2013396","journal-title":"Br J Haematol"},{"issue":"1","key":"5857_CR16","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/bjh.18012","volume":"197","author":"A Di Paola","year":"2022","unstructured":"Di Paola A et al (2022) Eltrombopag in paediatric immune thrombocytopenia: Iron metabolism modulation in mesenchymal stromal cells. Br J Haematol 197(1):110\u2013119","journal-title":"Br J Haematol"},{"issue":"Suppl 5","key":"5857_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000492187","volume":"41","author":"A Matzdorff","year":"2018","unstructured":"Matzdorff A et al (2018) Immune Thrombocytopenia - Current Diagnostics and Therapy: recommendations of a joint Working Group of DGHO, \u00d6GHO, SGH, GPOH, and DGTI. Oncol Res Treat 41(Suppl 5):1\u201330","journal-title":"Oncol Res Treat"},{"key":"5857_CR18","doi-asserted-by":"publisher","first-page":"205873841987212","DOI":"10.1177\/2058738419872120","volume":"33","author":"X Cheng","year":"2019","unstructured":"Cheng X et al (2019) Efficacy and safety of eltrombopag in the treatment of severe chronic immune thrombocytopenia in children of China: a single-center observational study. Int J Immunopathol Pharmacol 33:2058738419872120","journal-title":"Int J Immunopathol Pharmacol"},{"key":"5857_CR19","doi-asserted-by":"publisher","first-page":"953716","DOI":"10.3389\/fimmu.2022.953716","volume":"13","author":"Y Lv","year":"2022","unstructured":"Lv Y et al (2022) Current therapeutic strategies and perspectives in refractory ITP: what have we learned recently? Front Immunol 13:953716","journal-title":"Front Immunol"},{"issue":"11","key":"5857_CR20","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","volume":"113","author":"F Rodeghiero","year":"2009","unstructured":"Rodeghiero F et al (2009) Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 113(11):2386\u20132393","journal-title":"Blood"},{"issue":"19","key":"5857_CR21","doi-asserted-by":"publisher","first-page":"3799","DOI":"10.1182\/bloodadvances.2020004110","volume":"5","author":"X Cheng","year":"2021","unstructured":"Cheng X et al (2021) Spotlight on eltrombopag in pediatric ITP in China: a long-term observational study in real-world practice. Blood Adv 5(19):3799\u20133806","journal-title":"Blood Adv"},{"issue":"2","key":"5857_CR22","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/bjh.18842","volume":"202","author":"Z Wang","year":"2023","unstructured":"Wang Z et al (2023) Sustained response off treatment in eltrombopag for children with persistent\/chronic primary immune thrombocytopenia: a multicentre observational retrospective study in China. Br J Haematol 202(2):422\u2013428","journal-title":"Br J Haematol"},{"issue":"1","key":"5857_CR23","first-page":"32","volume":"44","author":"HP Sun","year":"2023","unstructured":"Sun HP et al (2023) [Maintenance of efficacy and its predictors after discontinuation of eltrombopag in adults with primary immune thrombocytopenia]. Zhonghua Xue Ye Xue Za Zhi 44(1):32\u201337","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"4","key":"5857_CR24","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1007\/s12185-017-2275-4","volume":"106","author":"TJ Gonz\u00e1lez-L\u00f3pez","year":"2017","unstructured":"Gonz\u00e1lez-L\u00f3pez TJ et al (2017) Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice. Int J Hematol 106(4):508\u2013516","journal-title":"Int J Hematol"},{"key":"5857_CR25","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3389\/fmed.2020.00066","volume":"7","author":"P Giordano","year":"2020","unstructured":"Giordano P et al (2020) Use of Eltrombopag in Children with Chronic Immune Thrombocytopenia (ITP): a Real Life Retrospective Multicenter experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP). Front Med (Lausanne) 7:66","journal-title":"Front Med (Lausanne)"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05857-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05857-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05857-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T13:02:25Z","timestamp":1722085345000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05857-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,25]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["5857"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05857-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4221716\/v1","asserted-by":"object"}]},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,25]]},"assertion":[{"value":"5 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}